FDA Greenlights Generic Party for Addiction Treatment Drug REVIA
Published Date: 4/16/2026
Notice
Summary
The FDA has decided that REVIA (naltrexone hydrochloride) 50 mg tablets weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of REVIA, helping patients access affordable options. No changes in safety rules or extra costs are expected, so things stay steady for doctors, patients, and pharmacies.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Generic Approvals Can Continue
On April 16, 2026, FDA determined that REVIA (naltrexone hydrochloride) 50 mg was not withdrawn from sale for reasons of safety or effectiveness. Because of that decision, FDA will continue to approve abbreviated new drug applications (ANDAs) that refer to REVIA as long as those ANDA applicants meet legal and regulatory requirements. This helps generic drug makers keep seeking approvals and can help patients access more affordable versions of REVIA.
Existing ANDA Approvals Preserved
FDA will not begin procedures to withdraw approval of any already-approved ANDAs that refer to REVIA (naltrexone hydrochloride) 50 mg. That means companies holding approved generic versions that reference REVIA keep their approvals in place rather than facing withdrawal procedures.
REVIA Remains in Orange Book Discontinued List
FDA will continue to list REVIA (naltrexone hydrochloride) 50 mg in the Orange Book’s "Discontinued Drug Product List," showing it was discontinued for reasons other than safety or effectiveness. The listing reflects that the NDA (018932) was withdrawn at the request of the sponsor and does not signal a safety or effectiveness problem.
Possible Labeling Updates for Generics
FDA said that if it determines labeling for REVIA should be revised to meet current standards, the Agency will advise ANDA applicants to submit updated labeling. That means future generic applicants may be asked to use revised labeling to match current regulatory expectations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-07450, Issuance of Multiple Exemptions
The Nuclear Regulatory Commission gave three special permissions to three different nuclear plant operators between January and March 2026. These exemptions let the operators do things a bit differently than usual, helping them run smoother without extra costs or delays. If you’re involved with these plants, keep an eye on the new rules and timelines!
Next: 2026-07452, Notice Announcing Teacher and School Leader Incentive Program Competition; Correction
The Department of Education and Labor fixed a small mistake in their Teacher and School Leader Incentive Program notice. The application deadline moved from June 8 to June 9, 2026, and they updated who can apply. If you’re a school or education agency interested in extra funding, don’t miss this new deadline!